89 results about "Cell generation" patented technology

A method and system is presented for storing data in data cells that contain only a single element of data. Each data cell includes four components: an Entity Instance identifier (“O”), an Entity Type identifier (“E”) an Attribute Type identifier (“A”), and an Attribute Value (“V”). Groups of cells with identical O and E values constitute a cell set, and contain information about a specific instance of an entity. Every cell contains a unique combination of O, E, A, and V, meaning that each cell is unique within any particular information universe. Relationships between cell sets are created through the use of linking or synapse cells that are created through a process of transmutation. In transmutation, two cell sets are associated with each other through the creation of two synapse cells. The first synapse cell has the O and E values of the first cell set, and has an A and V value equal to the E and O value, respectively, of the second cell set. The second synapse cell has the O and E values of the second cell set, and has as its A and V values the E and O value, respectively, of the first cell set. Through the use of cell generations, it is possible to store information about attributes, entities, relationships, constraints, and default data formats in the same cell listing as the cells containing the actual real-world data. As a result, the data in a data cell can be considered self-identifying. The present invention also provides a way to normalize data using data pool cell sets. The data cells themselves can be stored in multiple, co-existing storage trees that are specialized for increased data query efficiency.

To date, no immune tolerance agent or combination of immune tolerance agents has been able to sustain insulin-independence among type 1 diabetes patients. This patent provides methods and pharmaceutical compositions for providing insulin independence among newly diagnosed and existing type 1 diabetes. Methods include utilization of PPIs, which increase gastrin resulting in the transformation of human ductal tissue into insulin-secreting new beta cells, used in combination with an immune tolerance agent to protect the new insulin-producing beta cells generated by the PPI from immune destruction. Compositions and methods are provided for beta cell generation therapy comprising at least one member from a group of PPIs with formulations selected from immune tolerance agents, when used in combination result in insulin-independence among new and existing type 1 patients whom currently require insulin to sustain life. Compositions and methods are provided for insulin-independence among type 2 patients using PPIs when combined with therapeutic agents utilized for the treatment of type 2 diabetes.

The present disclosure provides methods of generating germ layers from stem cells comprising culturing the stem cells in a culture media having osmolality ranges that promote the generation of specific germ layer progenitor cells. The present disclosure also includes a method to generate different cell lineages from the germ layers as well as to detect them by immunological methods. The present disclosure further provides methods for the generation, isolation, cultivation and propagation of committed progenitor cells and for the production of differentiated cells from the three germ layers. The present disclosure also provides culture media and kits for use in inducing the three germ layers.